Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

NCT02535689 | Completed Phase 1

• 2 other identifiers: 15018515-AR-0185
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Systemic lupus erythematosus (lupus) is an autoimmune disease that often involves many systems and organs of the body. Symptoms can include fever, joint pains, and rashes. Serious lupus can also damage organs like the kidneys, lungs, or brain. Drugs used for lupus can have serious side effects. Also, the drugs don t help some people. Researchers want to find new, more effective and safe treatments. Objective: To evaluate the safety and tolerability of the drug tofacitinib (study drug) in people with lupus. Eligibility: People ages 18 and older who have mild to moderate lupus and are not currently or haven t recently had certain lupus treatments. Design: Participants will be screened in another protocol. Participants will have 7 five-hour visits over about 3 months. They will fill out multiple questionnaires. They will have tests, including:

• Physical exam
• Blood and urine tests
• ECG/EKG: Soft electrodes are stuck to the skin to monitor the heart.
• Optional SphygmoCor: Cuffs are attached to the arm and thigh to measure blood pressure and flow speed.
• Optional Endopat: A thimble-shaped cup is placed on the finger to measure blood flow. A cuff is put on the arm to measure blood pressure and flow.
• Optional CAVI: ECG electrodes are placed on both wrists, a microphone placed on the chest, and a blood pressure cuff placed on each arm and leg to measure blood pressure and velocity. Participants will receive either the study drug or a placebo. They will take this twice a day by mouth for 56 days. Participants will be contacted by phone 4 times....

Conditions

Systemic Lupus Erythematosus

Keywords

Anti-DNA Antibody; Tofacitinib; Lupus; Safety

Outcome Measures

Primary Outcomes (1)

• The primary endpoint is safety of tofacitinib in SLE subjects.

  5 years

Secondary Outcomes (2)

• Assessments of clinical response.

  5 years

• Assessment of biologic effects.

  5 years

Study Arms (3)

1

ACTIVE COMPARATOR

ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.

Drug: Tofacitinib

2

ACTIVE COMPARATOR

ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.

Drug: Tofacitinib

3

PLACEBO COMPARATOR

ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily.

Drug: Placebo

Interventions

Tofacitinib DRUG

Oral administration of tofacitinib, 5 mg

1; 2

Placebo DRUG

3

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is capable of providing written informed consent.
• Subject is greater than or equal to 18 years old.
• Meets at least 4 of 11 modified American College of Rheumatology (ACR) (1997) Revised Criteria for the Classification of Systemic Lupus Erythematosus.
• Has mild to moderate disease activity defined as a SLEDAI 2K more than or equal to 2 and less than or equal to 14 at the screening visit.
• If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable for the 4 weeks prior to screening visit.
• If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine, the dose must have been stable for the 12 weeks prior to screening visit. The maximum allowed dose is hydroxychloroquine up to 400 mg/day or 6.5 mg/kg/day if more than 400 mg/day. The maximum allowed dose for chloroquine phosphate is up to 500 mg daily and for quinacrine up to100 mg daily.
• Males and females with potential for reproduction must agree to practice effective birth control measures. Females should be on adequate contraception if they are of child-bearing potential documented by a clinician, unless patients or spouse have previously undergone a sterilization procedure. Adequate will be considered intrauterine device (IUD) alone or hormone implants, hormone patches, injectables, or oral contraceptives plus a barrier method (male condom, female condom or diaphragm), abstinence or a vasectomized partner
• If patients are on ACE inhibitors or ARB medications, dose of this medication must be stable for 4 weeks prior to study entry.
• Patients may be on lipid lowering medications if initiated at least 6 months prior to the screening visit.

You may not qualify if:

• Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test at screening.
• Current or prior treatment with rituximab, belimumab or any other biologic agent in the 6 months prior to screening.
• Patients previously on methotrexate, mycophenolate mofetil, cyclosporine or tacrolimus should have stopped it for at least 8 weeks at the time of screening.
• Treatment with cyclophosphamide, pulse methylprednisolone or IVIG within the 6 months prior to screening.
• Increase in glucocorticoid dose within 4 weeks of screening.
• A history of drug or alcohol abuse within the 6 months prior to screening.
• History of chronic liver disease or elevated LFTs:
• ALT or AST greater than or equal to 2x upper limit of normal at screening
• serum unconjugated bilirubin \> 2mg/dL at screening
• Dialysis or serum creatinine \>1.5mg/dL.
• Protein to creatinine ratio of more than 1 mg/mg or 24 hours urine protein of more than 1000 mg.
• Active urinary sediment (WBC, RBC or mixed cellular casts 1+ or more /hpf).
• Hypercholesterolemia: Values after an 8-12 hour fasting blood specimen: total cholesterol \>250 mg/dL or LDL \>180 mg/dl or hypertriglyceridemia (triglyceride \>300 mg/dL) within plus or minus 45 days of screening visit.
• Active infection that requires the use of oral or intravenous antibiotics and has not resolved at least 2 weeks prior to the administration of the first dose of study medication.
• Active chronic infections including but not limited to HIV, Hepatitis B, Hepatitis C, and BK viremia at screening visit.

Sponsors & Collaborators

• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (4)

• O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013 Jan 10;368(2):161-70. doi: 10.1056/NEJMra1202117. No abstract available.

  PMID: 23301733 BACKGROUND

• O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013 Mar;9(3):173-82. doi: 10.1038/nrrheum.2013.7. Epub 2013 Feb 19.

  PMID: 23419429 BACKGROUND

• Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.

  PMID: 21383241 BACKGROUND

• Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, O'Shea JJ, Gadina M, Kaplan MJ. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021 Jun 7;12(1):3391. doi: 10.1038/s41467-021-23361-z.

  PMID: 34099646 DERIVED

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Interventions

tofacitinib

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Sarfaraz A Hasni, M.D.

  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2015
• First Posted: August 31, 2015
• Study Start: August 28, 2015
• Primary Completion: April 26, 2018
• Study Completion: April 26, 2018
• Last Updated: August 9, 2018

Record last verified: 2018-04-25

Locations

US (1)